XILIO THERAPEUTICS INC (XLO) Stock Earnings & Estimates
USA - NASDAQ:XLO - US98422T1007 - Common Stock
0.8408 USD
0 (-0.02%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.344M | 39.314M 519.70% | 56.838M 44.57% | 16.281M -71.36% | 3.803M -76.64% | 2.712M -28.69% | 7.343M 170.76% | 1.515M -79.37% | 55.146M 3,540.00% | |||
| EBITDA YoY % growth | -87.3M -18.71% | -77.233M 11.53% | -58.001M 24.90% | -3.262M 94.38% | -57.57M -1,664.71% | -42.864M 25.54% | -38.168M 10.96% | -14.726M 61.42% | 115.85M 886.71% | N/A | N/A | |
| EBIT YoY % growth | -89.15M -18.80% | -79.133M 11.24% | -59.645M 24.63% | -49.288M 17.36% | -50.096M -1.64% | -118.625M -136.79% | -237.35M -100.09% | -296.94M -25.11% | -336.33M -13.27% | N/A | N/A | |
| Operating Margin | N/A | N/A | -940.18% | -125.37% | -88.14% | -728.61% | -6,241.13% | -10,949.12% | -4,580.28% | N/A | N/A | |
| EPS YoY % growth | -3.22 48.63% | -2.78 13.66% | -1.28 53.96% | -0.45 64.49% | -0.32 30.00% | -0.67 -111.11% | -0.48 27.82% | 0.37 176.04% | 1.10 198.63% | N/A | N/A |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.03 86.23% | -0.10 49.50% | -0.14 21.44% | -0.14 11.62% | -0.07 -133.33% | -0.07 30.00% |
| Revenue Q2Q % growth | 18.821M 731.68% | 9.373M 443.68% | 6.969M 137.85% | 6.06M -25.04% | 5.05M -73.17% | 4.545M -51.51% |
| EBITDA Q2Q % growth | -17.796M -31.49% | -202K 98.31% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -5.151M 65.20% | -15.706M -15.24% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.16 33.33% | -0.08 | -0.08 | -98.02% |
| Q1 2025 Q2Q % growth | -0.18 70.97% | 0.10 | -0.28 | -287.60% |
| Q4 2024 Q2Q % growth | -0.20 68.75% | -0.22 | 0.02 | 8.61% |
| Q3 2024 Q2Q % growth | -0.22 63.93% | -0.25 | 0.03 | 11.70% |
| Q2 2024 Q2Q % growth | -0.24 65.71% | -0.23 | -0.01 | -3.31% |
| Q1 2024 Q2Q % growth | -0.62 25.30% | -0.11 | -0.51 | -458.06% |
| Q4 2023 Q2Q % growth | -0.64 21.95% | -0.65 | 0.01 | 0.99% |
| Q3 2023 Q2Q % growth | -0.61 15.28% | -0.82 | 0.21 | 25.21% |
| Q2 2023 Q2Q % growth | -0.70 22.22% | -0.88 | 0.18 | 20.11% |
| Q1 2023 Q2Q % growth | -0.83 -6.41% | -0.89 | 0.06 | 7.22% |
| Q4 2022 Q2Q % growth | -0.82 16.33% | -0.79 | -0.03 | -3.42% |
| Q3 2022 Q2Q % growth | -0.72 96.61% | -0.89 | 0.17 | 18.76% |
| Q2 2022 Q2Q % growth | -0.90 | -0.79 | -0.11 | -14.10% |
| Q1 2022 Q2Q % growth | -0.78 | -0.94 | 0.16 | 16.80% |
| Q4 2021 Q2Q % growth | -0.98 | -1.18 | 0.20 | 16.80% |
| Q3 2021 Q2Q % growth | -21.27 | -1.61 | -19.66 | -1,218.27% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 8.084M 242.98% | 8.292M | -208K | -2.51% |
| Q1 2025 Q2Q % growth | 2.93M | 4.444M | -1.514M | -34.07% |
| Q4 2024 Q2Q % growth | 1.724M | 3.333M | -1.609M | -48.27% |
| Q3 2024 Q2Q % growth | 2.263M | 3.333M | -1.07M | -32.10% |
| Q2 2024 Q2Q % growth | 2.357M | 30.3M | -27.943M | -92.22% |
| Q1 2024 Q2Q % growth | 30.3M | -30.3M | -100.00% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 81.25% | -190.32% | 26.23% |
| Revenue | 0% | 151.82% | -42.73% | 54.9% |